Using AI, deep learning to fight aging

A Baltimore-based company is utilizing the power of artificial intelligence (AI) and deep learning to advance drug discovery, biomarker development and aging research.

Leveraging advanced AI, Insilico Medicine aims to use bioinformatics, research and development to extend patient lives.

“You have to look at the number of quality years of life you’re adding. If you include every individual on the planet, and you are adding one year of quality life to each of them, you’re generating 7.5 billion quality-adjusted life years,” said founder and CEO Alex Zhavoronkov, PhD. “That is the most altruistic decision to make. So if you go after aging, you are affecting the quality of life for everyone on the planet. The benefit of aging research generates the most benefit to society as a whole. If I can personally give one year of quality life to everyone, my life was very well spent.”

Read the full story from Forbes below:

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”